This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Lieff Cabraser Reminds Accretive Health Investors Of Upcoming Deadline In Putative Class Action Lawsuit – AH

Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the July 19, 2013 deadline to move for appointment as lead plaintiff in the securities putative class action brought on behalf all persons who purchased or otherwise acquired the securities of Accretive Health, Inc. (“Accretive” or the “Company”) (NYSE: AH) between May 20, 2010 and February 26, 2013, inclusive (the “Class Period”), including purchasers of the Company’s securities pursuant or traceable to the Company’s initial public offering (“IPO”) on or about May 20, 2010 and purchasers of the Company’s securities pursuant or traceable to the Company’s secondary public offering (“SPO”) on or about March 25, 2011.

If you purchased or otherwise acquired Accretive securities during the Class Period, including in connection with the Company’s IPO or SPO, you may move the Court for appointment as lead plaintiff by no later than July 19, 2013. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Accretive investors who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Michael J. Miarmi of Lieff Cabraser toll-free at 1-800-541-7358.

The Complaint charges Accretive and other defendants with violations of federal securities laws.

On February 26, 2013, the Company withdrew its financial guidance for fiscal 2012 and warned that, if it determined that it had incorrectly recognized revenue for its revenue cycle management agreements, it “may be required to restate prior-period financial statements.” On this news, shares of Accretive stock dropped $2.54 per share, or almost 21%, to close on February 27, 2013 at $9.57 per share. Subsequently, the Company disclosed that it would restate its historical financial statements for 2010, 2011, and 2012.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,985.61 +78.99 0.47%
S&P 500 1,972.83 +9.12 0.46%
NASDAQ 4,419.0340 +27.5710 0.63%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs